Comparing SG&A Expenses: Cytokinetics, Incorporated vs Galapagos NV Trends and Insights

Biotech Giants' SG&A Expenses: A Decade of Divergence

__timestampCytokinetics, IncorporatedGalapagos NV
Wednesday, January 1, 2014172680009079000
Thursday, January 1, 20151966700020309000
Friday, January 1, 20162782300016945000
Sunday, January 1, 20173646800020559000
Monday, January 1, 20183128200029641000
Tuesday, January 1, 20193961000088258000
Wednesday, January 1, 202052820000162170000
Friday, January 1, 202196803000167218000
Saturday, January 1, 2022177977000239528000
Sunday, January 1, 202317361200094252000
Loading chart...

Data in motion

SG&A Expenses: A Tale of Two Biotech Giants

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Over the past decade, Cytokinetics, Incorporated and Galapagos NV have demonstrated contrasting trends in their SG&A expenditures.

From 2014 to 2023, Cytokinetics saw a staggering increase of over 900% in their SG&A expenses, peaking in 2022. This surge reflects their aggressive expansion and investment in administrative capabilities. In contrast, Galapagos NV experienced a more volatile trajectory, with a significant spike in 2020, where expenses more than doubled compared to the previous year, before stabilizing in 2023.

These trends highlight the strategic differences between the two companies. While Cytokinetics focuses on steady growth, Galapagos NV appears to be navigating through periods of rapid change, possibly driven by strategic shifts or market conditions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025